|Bid||197.47 x 800|
|Ask||227.64 x 900|
|Day's Range||219.30 - 228.40|
|52 Week Range||121.80 - 277.00|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Inari Medical is the IBD Stock Of The Day as shares eye a fresh buy point. Shares of NARI stock have almost quadrupled from the asking price at the company's initial public offering in May.
(Bloomberg) -- Short seller Quintessential Capital Management raised concerns over the safety of Penumbra Inc.’s Jet 7 catheter for stroke victims in a new report Tuesday. Shares of the company tumbled in early trading.The report from New York-based QCM says Penumbra rushed to modify its Jet 7 Reperfusion Catheter device to compete with rivals and that the increased flexibility offered by the Jet 7 with Xtra Flex may have made it more prone to malfunction.Penumbra didn’t immediately respond to a Bloomberg email request for comment.Shares of the Alameda, California-based company sank as much as 7.9% at Tuesday’s open, the most in six months. Short reports aren’t new for the medical device company which was targeted by Spruce Point Capital Management LLC in July 2019. Since the money manager’s report the stock had rallied 35% through Monday’s close, double the return for the S&P 500.Bearish bets have increased with 16% of available Penumbra shares currently sold short, according to data compiled by S3 Partners. That’s the highest in more than a year, the data show.Gabriel Grego, founder of Quintessential Capital Management, has previously targeted companies including Italian bio-plastic company Bio-On SpA and Canadian pot firm Aphria Inc.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Shares of Penumbra (NYSE: PEN) were popping on Thursday, with the stock up 10.6% as of 12:15 p.m. EDT. The medical device maker announced better-than-expected third-quarter results after the market closed on Wednesday. Penumbra reported Q3 revenue of $151.1 million, up 8.3% year over year.